Healthcare Industry News: Novo Nordisk
News Release - November 7, 2006
Symphogen Appoints Christian Meyer Vice President of Clinical DevelopmentDr. Henrik Rasmussen Also Appointed to Symphogen's Medical Advisory Board
COPENHAGEN, Denmark--(HSMN NewsFeed)--Symphogen announced today that Christian Meyer, M.D., Ph.D., has been appointed Vice President of Clinical Development. In this role, Dr. Meyer will lead Symphogen's clinical development activities for its portfolio of recombinant polyclonal antibody product candidates and programs. The Company also announced the appointment of Henrik Rasmussen, M.D., Ph.D., of Nabi Biopharmaceuticals to its Medical Advisory Board.
"Christian brings to Symphogen more than ten years of clinical research and development experience from the biotech and pharmaceutical industries, as well as from academia," said Kirsten Drejer, Ph.D, CEO of Symphogen. "His understanding of the clinical development process and prior experience in project management will be valuable to Symphogen as we continue to cultivate our proprietary pipeline of recombinant human polyclonal antibody candidates."
Prior to joining Symphogen, Dr. Meyer was Director of Clinical Development at Zymenex A/S. Before joining Zymenex, Dr. Meyer served as the International Medical Officer at Novo Nordisk A/S, where he was responsible for planning human clinical trials and global development for a range of Novo Nordisk's biopharmaceuticals. During his tenure at Novo Nordisk, Dr. Meyer also held the positions of International Clinical Project Manager and Clinical Development Scientist. Dr. Meyer received a Ph.D. in Clinical Science and his M.D. from the University of Copenhagen, Denmark, after which he held several research fellow positions.
Henrik Rasmussen, M.D., Ph.D., who Symphogen has named to its Medical Advisory Board, is currently Senior Vice President of Clinical, Medical and Regulatory Affairs at Nabi Biopharmaceuticals. Dr. Rasmussen previously served as Senior Vice President of Clinical Research and Regulatory Affairs at GenVec, Vice President of Clinical Research and Senior Vice President of Clinical Research/Regulatory Affairs at British Biotech, and in various management positions within Pfizer Central Research's worldwide clinical development group. Dr. Rasmussen has helped author over 160 book chapters, original articles and scientific abstracts. He holds his M.D. and Ph.D. from the University of Copenhagen, Denmark.
Kirsten Drejer added, "With his experience from hyperimmune immunoglobulins and his general experience in global drug development, Dr. Rasmussen adds valuable clinical development expertise to our Medical Advisory Board, reflecting Symphogen's increased focus on the future clinical development of its recombinant polyclonal antibody product portfolio."
Symphogen is the leader in developing recombinant polyclonal antibodies (pAb), a new class of biopharmaceuticals for the treatment of serious human diseases. By employing its pioneering antibody discovery and manufacturing technologies, Symphogen generates recombinant antibody compositions that capture the diversity and effectiveness of the natural immune system. Symphogen is building a proprietary product pipeline within several disease areas, including infectious diseases and cancer. Symphogen has established collaborations with international pharmaceutical companies.
Sym001, Symphogen's lead program, is expected to be the first recombinant polyclonal antibody to enter clinical evaluation. Sym001 targets the treatments of Idiopathic Thrombocytopenic Purpura (ITP) and Hemolytic Disease of Newborns (HDN). Symphogen also has development alliances with Biovitrum AB. Symphogen is a private biopharmaceutical company with 70 employees, based in Copenhagen, Denmark.
Refer to www.symphogen.com for further information on Symphogen or please contact:
Kirsten Drejer, CEO of Symphogen: +45 45 26 50 59 or +45 22 10 99 59 (cell); email@example.com
John Haurum, CSO of Symphogen: +45 45 26 50 70 or +45 22 10 99 58 (cell); firstname.lastname@example.org
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.